BioCryst Pharmaceuticals (BCRX) Fundamental Analysis: Revenue, Earnings & Valuation

6.78 / 10

Outperform

Fundamental analysis yields a 6.78 score, rated Outperform. Strengths include high PB‑ROE (2.10), strong cash‑to‑market (1.76) and rapid revenue growth (94% YoY). Weak points are negative Asset‑MV and low gross margin. Overall, the balance sheet and growth metrics are encouraging.

Analysis Checks(7/10)

Revenue-MV

Value0.63

Score1/3

Weight28.92%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value94.10

Score3/3

Weight7.47%

1M Return1.54%

Inventory turnover ratio

Value2.83

Score2/3

Weight-5.39%

1M Return-1.21%

Gross profit margin (%)

Value97.82

Score0/3

Weight-28.07%

1M Return-7.24%

PB-ROE

Value2.10

Score3/3

Weight60.17%

1M Return9.74%

Income tax / Total profit (%)

Value1.32

Score3/3

Weight8.74%

1M Return1.47%

Fixed assets turnover ratio

Value45.13

Score2/3

Weight-2.55%

1M Return-0.51%

Cost of sales ratio (%)

Value2.18

Score2/3

Weight-18.43%

1M Return-4.42%

Asset-MV

Value-0.55

Score0/3

Weight15.06%

1M Return2.69%

Cash-MV

Value1.76

Score2/3

Weight34.08%

1M Return5.94%

Is BCRX fundamentally strong?

BCRX scores 6.78/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, 30.16% net margin, 9.05 P/E ratio, -20.04 P/B ratio, and 393.02% earnings growth, these metrics solidify its Outperform investment rating.